Ari VanderWalde

Global Head of Clinical Trials

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ari VanderWalde is the Global Head of Clinical Trials at Caris Life Sciences in the United States. His research focuses on the molecular mechanisms of cancer, particularly in relation to lipid metabolism, prognostic indicators in lung cancer, and personalized medicine strategies in oncology. His recent publications explore topics such as the role of SCD1 in lung adenocarcinoma, efficacy of targeted therapies in melanoma, and the impact of gene mutations on immune biomarkers in gastroesophageal cancers.

Articles (12)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Deniz Demircioglu

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Kangjin Jeong

Oregon Health & Science University

UNITED STATES

View details

Hirva Mamdani

Karmanos Cancer Institute

UNITED STATES

View details

Jonathan M. Loree

The University of British Columbia

CANADA

View details

Michael C. Wu

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ari VanderWalde

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

SCD1 Inhibition Blocks the AKT–NRF2–SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Personalized Medicine in Oncology; a Special Issue of the Journal of Personalized Medicine

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.

Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older patients with breast cancer.

Collaborators (5)

Deniz Demircioglu

Kangjin Jeong

Hirva Mamdani

Jonathan M. Loree

Michael C. Wu

Make your next move.